Brought to you by 
Yabao gets rights to annexin A5 in some Asian territories
02 May 2022
Executive Summary
Canada's Lawson Health Research Institute licensed Yabao Pharmaceutical Co. Inc. exclusive rights to discover, develop, and commercialize annexin A5-based sepsis treatments in China, Taiwan, and Hong Kong.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Yabao gets rights to annexin A5 in some Asian territories
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice